Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human Laminin alpha 1 ELISA Kit (AC2892)
Cat.#: ASET-1481
Specifications
Description Human Laminin alpha 1 ELISA Kit allows for the in vitro quantitative determination of human Laminin alpha 1 concentrations in serum, plasma, tissue homogenates, and other biological fluids. The kit employs the sandwich enzyme immunoassay technique. Size 96T Sample Type Serum, plasma, tissue homogenates, and other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.188 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 0.313-20 ng/mL Assay Time 4h 30m Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1754 Human TRPV2 ELISA Kit (AC3165) Quantitative inquiry ASET-2465 Human Syntaxin 1a ELISA Kit (AC3876) Quantitative inquiry ASET-2100 Rat TrkB ELISA Kit (AC3511) Quantitative inquiry ASET-1425 Mouse Synaptophysin ELISA Kit (AC2836) Quantitative inquiry ASET-1868 Human CASK ELISA Kit (AC3279) Quantitative inquiry ASET-1536 Mouse Mitofusin 1 ELISA Kit (AC2947) Quantitative inquiry ASET-1253 Human Hes1 ELISA Kit (AC2664) Quantitative inquiry ASET-2354 Human Renalase ELISA Kit (AC3765) Quantitative inquiry ASET-1163 Human Ephrin B1 ELISA Kit (AC2574) Quantitative inquiry ASET-2384 Mouse LECT2 ELISA Kit (AC3795) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket